Emivirine

Emivirine
Names
Preferred IUPAC name
6-Benzyl-1-(ethoxymethyl)-5-(propan-2-yl)pyrimidine-2,4(1H,3H)-dione
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C17H22N2O3/c1-4-22-11-19-14(10-13-8-6-5-7-9-13)15(12(2)3)16(20)18-17(19)21/h5-9,12H,4,10-11H2,1-3H3,(H,18,20,21) ☒N
    Key: MLILORUFDVLTSP-UHFFFAOYSA-N ☒N
  • InChI=1/C17H22N2O3/c1-4-22-11-19-14(10-13-8-6-5-7-9-13)15(12(2)3)16(20)18-17(19)21/h5-9,12H,4,10-11H2,1-3H3,(H,18,20,21)
    Key: MLILORUFDVLTSP-UHFFFAOYAG
  • CCOCN1C(=C(C(=O)NC1=O)C(C)C)CC2=CC=CC=C2
Properties
C17H22N2O3
Molar mass 302.36818 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Emivirine (MKC-442) is a failed experimental agent for the treatment of HIV. It is a non-nucleoside reverse transcriptase inhibitor.[1] While emivirine showed promising antiviral activity in vitro, it failed to show sufficient efficacy in human trials. However it is still notable as an early proof of concept, which led to the discovery of a number of related antiviral drugs.[2]

  1. ^ "Emivirine".
  2. ^ Calenbergh SV, Herdewijn P. A heterogeneous collection of novel antiviral pyrimidines. Expert Opinion on Therapeutic Patents 2000; 10(3):289-295. DOI:10.1517/13543776.10.3.289